Stock IVA INVENTIVA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Inventiva

Equities

IVA

FR0013233012

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:15 2024-04-26 am EDT 		5-day change 1st Jan Change
3 EUR -1.32% Intraday chart for Inventiva -5.96% -26.74%
Apr. 22 Inventiva: UBS Group falls below 5% threshold CF
Apr. 18 Transcript : Inventiva S.A. - Special Call

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 98.53 449.8 479.7 188.5 211.5 156 - -
Enterprise Value (EV) 1 62.8 354.2 444 136.3 211.5 247.8 319 156
P/E ratio -2.87 x -11.8 x -9.24 x -3.42 x -1.69 x -1.89 x -2.73 x -3 x
Yield - - - - - - - -
Capitalization / Revenue 14.1 x 1,209 x 114 x 15.4 x 12.1 x 36.8 x 11.6 x 12.9 x
EV / Revenue 8.97 x 952 x 106 x 11.2 x 12.1 x 58.5 x 23.6 x 12.9 x
EV / EBITDA -2.19 x -12.7 x -8.66 x -2.46 x - -2.59 x -4.18 x -2.09 x
EV / FCF -2.2 x -11.5 x -9.22 x -3 x - -3.6 x -7.67 x -
FCF Yield -45.4% -8.72% -10.8% -33.4% - -27.8% -13% -
Price to Book 2.38 x 4.07 x 5.17 x 4.15 x - -1.48 x -1.06 x -
Nbr of stocks (in thousands) 26,846 38,379 40,859 42,120 51,647 52,010 - -
Reference price 2 3.670 11.72 11.74 4.475 4.095 3.000 3.000 3.000
Announcement Date 3/10/20 3/4/21 2/14/22 3/29/23 3/27/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 6.998 0.372 4.2 12.2 17.48 4.236 13.49 12.08
EBITDA 1 -28.73 -27.83 -51.27 -55.41 - -95.75 -76.24 -74.67
EBIT 1 -30.31 -29.72 -51.16 -57.11 -102.7 -115.2 -98.69 -119.3
Operating Margin -433.15% -7,988.71% -1,218.14% -468.11% -587.68% -2,719.1% -731.38% -987.33%
Earnings before Tax (EBT) 1 -30.22 -33.62 -49.27 -54.29 -109.8 -123 -128.5 -123.6
Net income 1 -30.22 -33.62 -49.64 -54.27 -110.4 -112.9 -90.52 -123.6
Net margin -431.81% -9,037.37% -1,181.79% -444.87% -631.84% -2,664.05% -670.78% -1,022.63%
EPS 2 -1.280 -0.9900 -1.270 -1.310 -2.430 -1.590 -1.100 -1.000
Free Cash Flow 1 -28.54 -30.88 -48.16 -45.49 - -68.9 -41.57 -
FCF margin -407.83% -8,301.61% -1,146.74% -372.86% - -1,626.38% -308.03% -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 3/10/20 3/4/21 2/14/22 3/29/23 3/27/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 Q2 2023 S1 2023 Q4 2023 S2 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2
Net sales 1 5.665 1.768 0.211 0.139 4.061 0.1 12.1 1.901 1.9 15.58 15.58 1.389 1.389 3.083 1.389 1.389 3.417
EBITDA 1 - - - - - - - - - - - -22.96 -25.32 - -26.29 -24.49 -
EBIT 1 -9.656 -15.66 -14.05 -23.2 -27.97 -33.47 -23.64 - -55 - -47.71 -22.96 -25.32 -62.47 -26.29 -24.49 -63.63
Operating Margin -170.45% -886.03% -6,660.19% -16,687.05% -688.67% -33,468% -195.39% - -2,894.89% - -306.28% -1,653.33% -1,823.33% -2,025.95% -1,893.33% -1,763.33% -1,862.44%
Earnings before Tax (EBT) -9.673 -15.66 -17.96 -22.78 -26.49 -29.48 -24.81 - -55.28 - -54.54 - - -60.82 - - -62.15
Net income -9.673 -15.66 -17.96 -23.14 -26.5 -29.47 -24.81 - -55.27 - -55.16 - - -60.82 - - -62.15
Net margin -170.75% -885.69% -8,511.85% -16,644.6% -652.52% -29,466% -205.02% - -2,908.89% - -354.12% - - -1,972.43% - - -1,819.02%
EPS -0.3500 -0.5200 -0.4700 -0.6000 -0.6700 -0.7200 -0.5900 - -1.310 - -1.120 - - -0.7700 - - -0.6200
Dividend per Share - - - - - - - - - - - - - - - - -
Announcement Date 3/10/20 9/16/20 3/4/21 9/20/21 2/14/22 9/22/22 3/29/23 7/27/23 7/27/23 3/27/24 3/27/24 - - - - - -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - 91.7 163 -
Net Cash position 1 35.7 95.6 35.7 52.2 - - - -
Leverage (Debt/EBITDA) - - - - - -0.9581 x -2.138 x -
Free Cash Flow 1 -28.5 -30.9 -48.2 -45.5 - -68.9 -41.6 -
ROE (net income / shareholders' equity) -58.7% -44.1% -49.6% -80.8% - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 1.540 2.880 2.270 1.080 - -2.030 -2.830 -
Cash Flow per Share 2 -1.210 -0.9000 -1.220 -1.080 - -0.8000 - -
Capex 1 0.11 0.29 0.53 0.56 - 0.55 0.55 0.7
Capex / Sales 1.53% 78.49% 12.71% 4.6% - 12.98% 4.08% 5.79%
Announcement Date 3/10/20 3/4/21 2/14/22 3/29/23 3/27/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Inventiva

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3 EUR
Average target price
13.83 EUR
Spread / Average Target
+361.11%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
INVENTIVA Stock Inventiva
-26.74% 167M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. IVA Stock
  4. Financials Inventiva